| 淋巴瘤化疗后行大剂量IL-2免疫治疗对长期生存的影响 |
| |
| 引用本文： | 刘昊,郭智. 淋巴瘤化疗后行大剂量IL-2免疫治疗对长期生存的影响[J]. 实用癌症杂志, 2011, 26(2): 190-192 |
| |
| 作者姓名： | 刘昊 郭智 |
| |
| 作者单位： | 1. 100700,北京军区总医院血液科;230032安徽医科大学第一临床学院
2. 北京军区总医院血液科,100700 |
| |
| 摘 要： | 目的探讨恶性淋巴瘤化疗缓解后行大剂量白介素-2（IL-2）免疫治疗的临床疗效。方法 2005年1月～2010年5月共40例淋巴瘤患者（治疗组）化疗缓解后进行大剂量IL-2免疫治疗,随机挑选的40例患者（对照组）,化疗结束缓解后不进行任何免疫治疗,检测两组患者外周血T淋巴细胞亚群,并对所有患者进行随访观察。结果治疗组外周血T淋巴细胞亚群水平明显提升,随访结束时统计复发率：治疗组17.5%,对照组32.5%;中位生存期：治疗组（34.5±2.0）（20～60）个月,对照组（23.2±2.0）（12～60）个月。结论恶性淋巴瘤化疗缓解后行大剂量IL-2治疗是有效的免疫治疗手段,能提高患者的免疫功能,减少复发率,延长生存期,具有潜在临床应用前景。
|
| 关 键 词： | 淋巴瘤 白细胞介素-2 过继免疫治疗 长期生存 |
The Effect of High-dose Interleukin-2 Immunotherapy after Chemotherapy of Lymphoma to Long-term Survival |
| |
| LIU Hao,GUO Zhi. The Effect of High-dose Interleukin-2 Immunotherapy after Chemotherapy of Lymphoma to Long-term Survival[J]. The Practical Journal of Cancer, 2011, 26(2): 190-192 |
| |
| Authors: | LIU Hao GUO Zhi |
| |
| Affiliation: | LIU Hao,GUO Zhi.Department of Hematology,General Hospital,Beijing Military Area,Beijing,100700 |
| |
| Abstract: | Objective study the clinical efficacy of high-dose interleukin-2(IL-2) immunotherapy after chemotherapy of malignant lymphoma.Methods review 40 malignant lymphoma patients treated with high-dose interleukin-2 after they had treated with chemotherapy and acquired remission,compared with 40 randomly selected malignant lymphoma patients without immunotherapy after they had treated with chemotherapy and acquired remission of Beijing Military General Hospital from January 2005 to May 2010.Detect T lymphocyte sub... |
| |
| Keywords: | Malignant Lymphoma Interleukin-2 Adoptive Immunotherapy Long-term Survival |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
